Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A, Kapitza C, Zdravkovic M. Flint A, et al. Diabetes Obes Metab. 2013 Oct;15(10):958-62. doi: 10.1111/dom.12108. Epub 2013 Apr 23. Diabetes Obes Metab. 2013. PMID: 23551925 Clinical Trial.
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Heise T, et al. Diabetes. 2004 Jun;53(6):1614-20. doi: 10.2337/diabetes.53.6.1614. Diabetes. 2004. PMID: 15161770 Clinical Trial.
Insulin detemir also provided less within-subject variability in the pharmacokinetic end points: maximal concentration (C(max)) 18 vs. 24 vs. 34%; INS-AUC((0- infinity )) 14 vs. 28 vs. 33%. ...
Insulin detemir also provided less within-subject variability in the pharmacokinetic end points: maximal concentration (C(max)) 18 vs …
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Nauck MA, et al. Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14. Diabetes Care. 2009. PMID: 19366970 Free PMC article. Clinical Trial.
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. Heinemann L, et al. Diabetes Care. 2009 Aug;32(8):1437-9. doi: 10.2337/dc09-0595. Epub 2009 Jun 1. Diabetes Care. 2009. PMID: 19487635 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. Kapitza C, et al. Diabet Med. 2009 Nov;26(11):1156-64. doi: 10.1111/j.1464-5491.2009.02854.x. Diabet Med. 2009. PMID: 19929995 Clinical Trial.
Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes.
Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Kapitza C, et al. Diabetes Care. 2010 Jun;33(6):1288-90. doi: 10.2337/dc09-1807. Epub 2010 Feb 25. Diabetes Care. 2010. PMID: 20185734 Free PMC article. Clinical Trial.
RESULTS: Maximum insulin concentration was greater and onset of action was faster with OI (C(max) 93 +/- 71 vs. 33 +/- 11 microU/ml; AUC(GIR)((0-1h)) 173 +/- 86 vs. 27 +/- 32 mg/kg; P < 0.05). ...
RESULTS: Maximum insulin concentration was greater and onset of action was faster with OI (C(max) 93 +/- 71 vs. 33 +/- 11 microU/ml; …
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C. Arnolds S, et al. Diabetes Care. 2010 Jul;33(7):1509-15. doi: 10.2337/dc09-2191. Epub 2010 Mar 31. Diabetes Care. 2010. PMID: 20357372 Free PMC article. Clinical Trial.
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Ratner R, et al. Diabet Med. 2010 May;27(5):556-62. doi: 10.1111/j.1464-5491.2010.02990.x. Diabet Med. 2010. PMID: 20536952 Free PMC article. Clinical Trial.
Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A. Kapitza C, et al. J Clin Pharmacol. 2011 Jun;51(6):951-5. doi: 10.1177/0091270010374474. Epub 2010 Jul 29. J Clin Pharmacol. 2011. PMID: 20671294 Clinical Trial. No abstract available.
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R. Bonadonna RC, et al. J Clin Endocrinol Metab. 2010 Nov;95(11):5028-36. doi: 10.1210/jc.2010-1041. Epub 2010 Aug 25. J Clin Endocrinol Metab. 2010. PMID: 20739378 Clinical Trial.
62 results
Jump to page
Feedback